[The heterogeneity of the immunological phenotype and of the proliferative characteristics of the lymphoid cells in chronic B-cell lympholeukemia].
Patients with stage III and IV (according to Rai) B-cell chronic lymphocytic leukemia (B-CLL) were shown to differ in the expression of markers such as HLA-DR, RFB-1, CD-18, CD-21, activated B-lymphocyte antigen and B-lymphocyte differentiation antigen on mononuclear fraction cells (MFC). Also, differences in the level of MFC proliferation activity during a 72-hour culturing in vitro were established. Some patients with B-CLL showed an increase in lymphocyte proliferation activity in response to treatment with growth factor recombinant interleukin (IL-2) alone and in combination with phytohemagglutinin and phorbol ester. Those changes most often occurred in cases with decreased spontaneous proliferation in culture.
Kariagin
I E
IE
Tsveĭbakh
A S
AS
Afanas'ev
B V
BV
D000368:Aged; D000911:Antibodies, Monoclonal; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured / Q000166:cytology / Q000187:drug effects; D005455:Fluorescent Antibody Technique; D006801:Humans; D016130:Immunophenotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000276:immunology*; D008214:Lymphocytes / Q000166:cytology* / Q000187:drug effects; D008875:Middle Aged; D012397:Rosette Formation
D000911:Antibodies, Monoclonal
Geterogennost' immunologicheskogo fenotipa i proliferativnykh kharakteristik limfoidnykh kletok pri B-kletochnom khronicheskom limfoleĭkoze.